Literature DB >> 29550075

Polymer-Mediated Inhibition of Pro-invasive Nucleic Acid DAMPs and Microvesicles Limits Pancreatic Cancer Metastasis.

Ibtehaj Naqvi1, Ruwan Gunaratne1, Jessica E McDade2, Angelo Moreno2, Rachel E Rempel2, Douglas C Rouse3, Silvia Gabriela Herrera4, David S Pisetsky5, Jaewoo Lee2, Rebekah R White6, Bruce A Sullenger7.   

Abstract

Nucleic acid binding polymers (NABPs) have been extensively used as vehicles for DNA and RNA delivery. More recently, we discovered that a subset of these NABPs can also serve as anti-inflammatory agents by capturing pro-inflammatory extracellular nucleic acids and associated protein complexes that promote activation of toll-like receptors (TLRs) in diseases such as lupus erythematosus. Nucleic-acid-mediated TLR signaling also facilitates tumor progression and metastasis in several cancers, including pancreatic cancer (PC). In addition, extracellular DNA and RNA circulate on or within lipid microvesicles, such as microparticles or exosomes, which also promote metastasis by inducing pro-tumorigenic signaling in cancer cells and pre-conditioning secondary sites for metastatic establishment. Here, we explore the use of an NABP, the 3rd generation polyamidoamine dendrimer (PAMAM-G3), as an anti-metastatic agent. We show that PAMAM-G3 not only inhibits nucleic-acid-mediated activation of TLRs and invasion of PC tumor cells in vitro, but can also directly bind extracellular microvesicles to neutralize their pro-invasive effects as well. Moreover, we demonstrate that PAMAM-G3 dramatically reduces liver metastases in a syngeneic murine model of PC. Our findings identify a promising therapeutic application of NABPs for combating metastatic disease in PC and potentially other malignancies.
Copyright © 2018 The American Society of Gene and Cell Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  damage-associated molecular patterns; metastasis; nucleic acid binding polymer

Mesh:

Substances:

Year:  2018        PMID: 29550075      PMCID: PMC6079560          DOI: 10.1016/j.ymthe.2018.02.018

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   12.910


  61 in total

1.  Nucleic acid-binding polymers as anti-inflammatory agents.

Authors:  Jaewoo Lee; Jang Wook Sohn; Ying Zhang; Kam W Leong; David Pisetsky; Bruce A Sullenger
Journal:  Proc Natl Acad Sci U S A       Date:  2011-08-15       Impact factor: 11.205

Review 2.  Tumor-Induced NETosis as a Risk Factor for Metastasis and Organ Failure.

Authors:  Jessica Cedervall; Yanyu Zhang; Anna-Karin Olsson
Journal:  Cancer Res       Date:  2016-07-11       Impact factor: 12.701

Review 3.  Cell-free nucleic acids as biomarkers in cancer patients.

Authors:  Heidi Schwarzenbach; Dave S B Hoon; Klaus Pantel
Journal:  Nat Rev Cancer       Date:  2011-05-12       Impact factor: 60.716

4.  Effects of CPG ODN on biological behavior of PANC-1 and expression of TLR9 in pancreatic cancer.

Authors:  Han-Qing Wu; Bo Wang; Shi-Kai Zhu; Yuan Tian; Jing-Hui Zhang; He-Shui Wu
Journal:  World J Gastroenterol       Date:  2011-02-28       Impact factor: 5.742

5.  Inhibitory oligonucleotides specifically block effects of stimulatory CpG oligonucleotides in B cells.

Authors:  Laura L Stunz; Petar Lenert; David Peckham; Ae-Kyung Yi; Sokol Haxhinasto; Ming Chang; Arthur M Krieg; Robert F Ashman
Journal:  Eur J Immunol       Date:  2002-05       Impact factor: 5.532

6.  Nucleic acid scavengers inhibit thrombosis without increasing bleeding.

Authors:  Shashank Jain; George A Pitoc; Eda K Holl; Ying Zhang; Luke Borst; Kam W Leong; Jaewoo Lee; Bruce A Sullenger
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-25       Impact factor: 11.205

7.  Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial.

Authors:  Helmut Oettle; Peter Neuhaus; Andreas Hochhaus; Jörg Thomas Hartmann; Klaus Gellert; Karsten Ridwelski; Marco Niedergethmann; Carl Zülke; Jörg Fahlke; Michael B Arning; Marianne Sinn; Axel Hinke; Hanno Riess
Journal:  JAMA       Date:  2013-10-09       Impact factor: 56.272

Review 8.  Clinical experiences with systemically administered siRNA-based therapeutics in cancer.

Authors:  Jonathan E Zuckerman; Mark E Davis
Journal:  Nat Rev Drug Discov       Date:  2015-11-16       Impact factor: 84.694

Review 9.  Recognition of nucleic acids by pattern-recognition receptors and its relevance in autoimmunity.

Authors:  Takumi Kawasaki; Taro Kawai; Shizuo Akira
Journal:  Immunol Rev       Date:  2011-09       Impact factor: 12.988

10.  Nucleic acid scavenging polymers inhibit extracellular DNA-mediated innate immune activation without inhibiting anti-viral responses.

Authors:  Eda K Holl; Kara L Shumansky; George Pitoc; Elizabeth Ramsburg; Bruce A Sullenger
Journal:  PLoS One       Date:  2013-07-23       Impact factor: 3.240

View more
  12 in total

1.  Irreversible Electroporation Combined with Checkpoint Blockade and TLR7 Stimulation Induces Antitumor Immunity in a Murine Pancreatic Cancer Model.

Authors:  Jayanth S Shankara Narayanan; Partha Ray; Tomoko Hayashi; Thomas C Whisenant; Diego Vicente; Dennis A Carson; Aaron M Miller; Stephen P Schoenberger; Rebekah R White
Journal:  Cancer Immunol Res       Date:  2019-08-13       Impact factor: 11.151

2.  Keep Quiet and Stay in Line! Smart Polymers to Keep an Eye on Pancreatic Tumors.

Authors:  Pierre Cordelier
Journal:  Mol Ther       Date:  2018-03-19       Impact factor: 11.454

3.  β-Cyclodextrin-containing polymer treatment of cutaneous lupus and influenza improves outcomes.

Authors:  Linsley Kelly; Lyra B Olson; Rachel E Rempel; Jeffrey I Everitt; Dana Levine; Smita K Nair; Mark E Davis; Bruce A Sullenger
Journal:  Mol Ther       Date:  2021-10-08       Impact factor: 11.454

Review 4.  Targeting DAMPs with nucleic acid scavengers to treat lupus.

Authors:  Lyra B Olson; Nicole I Hunter; Rachel E Rempel; Bruce A Sullenger
Journal:  Transl Res       Date:  2022-03-02       Impact factor: 10.171

5.  Nanotechnology for Pain Management: Current and Future Therapeutic Interventions.

Authors:  Divya Bhansali; Shavonne L Teng; Caleb S Lee; Brian L Schmidt; Nigel W Bunnett; Kam W Leong
Journal:  Nano Today       Date:  2021-06-19       Impact factor: 18.962

6.  Controlling cancer-induced inflammation with a nucleic acid scavenger prevents lung metastasis in murine models of breast cancer.

Authors:  Eda K Holl; Victoria Frazier; Karenia Landa; David Boczkowski; Bruce Sullenger; Smita K Nair
Journal:  Mol Ther       Date:  2020-12-19       Impact factor: 11.454

Review 7.  Drug delivery carriers with therapeutic functions.

Authors:  Shuting S Cai; Tianyu Li; Tolulope Akinade; Yuefei Zhu; Kam W Leong
Journal:  Adv Drug Deliv Rev       Date:  2021-07-21       Impact factor: 17.873

8.  Treatment of severe sepsis with nanoparticulate cell-free DNA scavengers.

Authors:  Jianati Dawulieti; Madi Sun; Yawei Zhao; Dan Shao; Huize Yan; Yeh-Hsing Lao; Hanze Hu; Lianzhi Cui; Xiaoyan Lv; Feng Liu; Chun-Wei Chi; Yue Zhang; Mingqiang Li; Ming Zhang; Huayu Tian; Xuesi Chen; Kam W Leong; Li Chen
Journal:  Sci Adv       Date:  2020-05-29       Impact factor: 14.136

Review 9.  Tumor-Associated Macrophages in Pancreatic Ductal Adenocarcinoma: Origin, Polarization, Function, and Reprogramming.

Authors:  Sen Yang; Qiaofei Liu; Quan Liao
Journal:  Front Cell Dev Biol       Date:  2021-01-11

10.  A nanoparticulate dual scavenger for targeted therapy of inflammatory bowel disease.

Authors:  Chengxin Shi; Jianati Dawulieti; Feiyu Shi; Chao Yang; Qian Qin; Tongfei Shi; Lizhao Wang; Hanze Hu; Madi Sun; Li Ren; Fangman Chen; Yawei Zhao; Feng Liu; Mingqiang Li; Lijun Mu; Dan Liu; Dan Shao; Kam W Leong; Junjun She
Journal:  Sci Adv       Date:  2022-01-28       Impact factor: 14.136

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.